#USA #New York #Scientific Advisory Board #infusion therapy #EMED Technologies

EMED Technologies Establishes a New Scientific Advisory Board

In a significant move to enhance its innovative capabilities in drug delivery and infusion therapy solutions, EMED Technologies has announced the establishment of its new Scientific Advisory Board (SAB). As a pioneer in the field established in 1991, EMED focuses on developing cutting-edge devices that enable subcutaneous infusion for biologics, specialty medications, and home treatments. These innovations aim to improve patient independence, deliver precision in care, and ensure comfort and reliability in treatment accessibility.

Leadership Insights

Dr. Alex Nikanorov, M.D., Ph.D., who serves as EMED's Director of Clinical Affairs, expressed his enthusiasm regarding the formation of the SAB, highlighting the incredible expertise and experience brought forth by the members. He stated, "We have formed a scientific partnership with these distinguished doctors who embody EMED’s mission. I am honored to collaborate with such an exceptional group to innovate medical solutions that focus on patient-centric technology and improved clinical outcomes."

Members of the SAB

The newly assembled board consists of three leading figures renowned in their respective fields:

1. Dr. Jeffrey Allen, M.D.: An expert neurologist, his work primarily focuses on inflammatory neuropathy, muscular dystrophy, Guillain-Barre Syndrome, among others. With affiliations at prestigious institutions, including the University of Minnesota, Dr. Allen also plays a significant role in educating future neurologists as an Assistant Professor in the University of Minnesota’s Department of Neurology.

2. Dr. Richard Wasserman, M.D., Ph.D.: A dedicated allergist and immunologist with specialties in food allergy and primary immunodeficiency, Dr. Wasserman has garnered extensive training and experience across top medical institutions. His exceptional academic background includes completing a fellowship in Bone Marrow Transplantation/Immunology at the Children’s Hospital of Philadelphia and a Ph.D. in Biomedical Sciences.

3. Dr. Jack Lewin, M.D.: Recognized for his leadership as the founder of Lewin and Associates LLC and as Chairman of the National Coalition on Health, Dr. Lewin brings a wealth of strategic insight and health policy innovation to the team. His experience advising high-level government officials further enhances the board with national policy expertise aimed at creating an efficient healthcare system.

Objectives and Future Directions

The SAB members are tasked with advising EMED Technologies’ leadership on both scientific and strategic initiatives. Their collective knowledge is expected to steer the company towards producing next-generation drug delivery systems focused on subcutaneous infusion. With such a foundation of expertise, EMED aims to set a new standard for health solutions by delivering innovations that meet the evolving needs of patients and healthcare providers.

With this new board in place, EMED Technologies is well-positioned to enhance its development pipeline and solidify its presence as a leading contributor in the field of infusion therapy and drug delivery technology. The company is committed to continuous improvement and innovation to ensure that patients receive the highest standard of care possible, aligning with its mission to empower individuals with user-friendly and effective treatment options.

As advancements in infusion technologies evolve, EMED seeks to lead the charge, leveraging the insights and advancements that its Scientific Advisory Board will help to foster. This commitment marks a pivotal moment not only for EMED Technologies but also for the future of patient-centric medical technology.